Evidence map›Paper›PMID 42538939›Full record

ArticlebioRxiv : the preprint server for biology2026

Combination siRNA delivery as a therapeutic strategy for ADPKD.

Joshua Giblin, Isabella Suzuki, Yi Huang, Karla Lambaren, Ronnie LaMastro, Rowan Simon, Jose Zarate-Diaz, Ali Osouli, Jessica Pham, Soobeen Laura Bae and 2 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Joshua GiblinAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.ORCID 0009-0005-0909-6955
Isabella SuzukiAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.
Yi HuangAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.ORCID 0000-0002-6418-4414
Karla LambarenAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.
Ronnie LaMastroAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.
Rowan SimonAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.
Jose Zarate-DiazAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.
Ali OsouliAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.
Jessica PhamDepartment of Medicine, Division of Nephrology, University of Vermont Health, Burlington, Vermont, 05405, USA.
Soobeen Laura BaeSilver Spur Therapeutics, Inc, Palos Verdes Peninsula, CA, 90274, USA.
Kenneth HallowsDepartment of Medicine, Division of Nephrology, University of Vermont Health, Burlington, Vermont, 05405, USA.
Eun Ji ChungAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.ORCID 0000-0002-7726-5555

Funding

Coordinating Unit for the Innovative Science Accelerator ProgramU24DK128851 · NIDDK · AUGUSTA UNIVERSITY · PI MCINDOE, RICHARD A. · 2021 to 2025
$6.7M
Resource Development CoreU54DK137516 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Evan Alexander Scott · 2023 to 2026
$4.8M
NIDDK NIH HHS U24 DK128851NIDDK NIH HHS U54 DK137516
6 · The paper itself

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease worldwide, characterized by progressive cyst growth and inflammation, yet effective targeted therapies remain limited. Here we show that TMEM16A and MCP-1, key mediators of cyst-lining epithelial expansion and inflammatory macrophage recruitment respectively, are consistently upregulated in cyst-lining collecting duct (CD) epithelia across murine, porcine, and human ADPKD models. In human ADPKD patient cells, although individual silencing of

Indexed as

ADPKDChronic Kidney DiseaseDrug DeliveryGene TherapyMicellesNanomedicinesiRNA

Identifiers

PMID42538939
PMCPMC13419467

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.